Skip to main content
Equibles
ALKS logo

ALKS · Alkermes plc. · Metrics

Track ALKS — free

Use ALKS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALKS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$43.78 -0.33 (-0.75%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$7.43B
Shares
167.76M
Volume · Oct 21 806.65K Avg daily vol (3M) 1.92M

ALKS metrics

103 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$44.11
Market cap
$7.43B

Price action

20 metrics
Price change (1W)
+11.0%
Price change (30D)
-0.2%
Price change (3M)
-16.5%
Price change (6M)
+31.6%
Price change (YTD)
+57.6%
Price change (1Y)
+42.4%
Trailing year
Price change (5Y)
+42.9%
52-week high
$55.22
52-week low
$27.20
Change from 52-week high
-20.1%
Change from 52-week low
+62.2%
Annualized volatility
40.8%
Annualized volatility (3M)
33.4%
Beta
0.8
RSI (14D)
57.7
Price vs SMA 50
-1.6%
Price vs SMA 200
+10.6%
Avg volume (3M)
1.92M
Relative volume
1.2
Average dollar volume
$86.88M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
167.76M

Valuation

12 metrics
P / E (TTM)
116.1
Trailing earnings · reciprocal yield 0.9%
PEG ratio
—
EV / revenue
5.0×
reciprocal yield 19.8%
EV / EBITDA
47.1×
reciprocal yield 2.1%
EV / EBIT
71.8×
reciprocal yield 1.4%
P / sales
4.5×
reciprocal yield 22.5%
P / book
4.1
reciprocal yield 24.4%
FCF yield
—
TTM · current market cap
Buyback yield
1.6%
P / FCF
—
P / operating cash flow
29.6
reciprocal yield 3.4%
Earnings yield
0.9%

Historical valuation

8 metrics
P / E historical average (3Y)
27.1×
reciprocal yield 3.7%
P / E historical average (5Y)
29.1×
reciprocal yield 3.4%
EV / revenue historical average (3Y)
3.3×
reciprocal yield 30.5%
EV / revenue historical average (5Y)
3.5×
reciprocal yield 28.5%
EV / EBIT historical average (3Y)
21.2×
reciprocal yield 4.7%
EV / EBIT historical average (5Y)
22.9×
reciprocal yield 4.4%
EV / EBITDA historical average (3Y)
18.1×
reciprocal yield 5.5%
EV / EBITDA historical average (5Y)
463.9×
reciprocal yield 0.2%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.6%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-03
Last earnings
2026-07-28

Profitability

9 metrics
Gross margin
84.6%
Operating margin
7.0%
Trailing 12 months
Net margin
4.0%
Gross profit (TTM)
$1.41B
Operating profit (TTM)
$117.26M
Net income (TTM)
$66.12M
Trailing 12 months
Diluted EPS (TTM)
$0.38
FCF margin
—
Effective tax rate
32.1%

Per share

11 metrics
Revenue per diluted share (TTM)
$9.83
Gross profit per diluted share (TTM)
$8.32
Operating profit per diluted share (TTM)
$0.69
EBITDA per diluted share (TTM)
$1.05
Net income per diluted share (TTM)
$0.39
Operating cash flow per diluted share (TTM)
$1.45
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$2.31
Stock compensation per diluted share (TTM)
$0.70
Book value per share
$10.99

Growth

11 metrics
Revenue growth YoY
+27.0%
Year over year
Net income growth YoY
-99.4%
Revenue (TTM)
$1.67B
Trailing 12 months
EPS growth YoY
-100.0%
Shares change YoY
+3.0%
Year over year · more shares
Revenue CAGR (3Y)
+9.9%
Revenue CAGR (5Y)
+7.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
+63.9%

Quality

14 metrics
Return on equity
3.7%
Return on assets
1.5%
Debt / equity
0.8
Current ratio
2.3
EBITDA (TTM)
$178.89M
Free cash flow (TTM)
—
Quick ratio
1.8
Interest coverage
2.0
Net debt / EBITDA
5.5
Return on invested capital
2.8%
Trailing 12 months
Net cash
−$991.58M
Latest balance sheet
Cash & equivalents
$511.53M
Total assets
$4.39B
Total debt
$1.50B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$251.18M
Capital expenditures (TTM)
$29.53M
R&D (TTM)
$391.04M
SG&A (TTM)
$841.19M
Stock compensation (TTM)
$118.41M
R&D / revenue
23.4%
Stock compensation / revenue
7.1%

Ownership (13F)

9 metrics
13F filers
426
13F filer change QoQ
+34
Institutional ownership
107.2%
Conviction holders (share of 13F filers)
2.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-1.4%
Holder tenure
13.9
Price vs estimated holder cost
+67.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.3%

Short interest

3 metrics
Short interest
10.6%
Latest settlement · 6.3 days to cover
Days to cover
6.3d
Short-squeeze score
79 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.75M
Insider-sentiment score
34 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1520262 CUSIP G01767105 13F (30d) 44 filings 44 filers Visit website Investor relations